China Medical System Acquires Rights to Novartis Drugs

China Medical System Holdings of Shenzhen acquired China rights to two Novartis drugs: Lamisil, an antifungal medication used especially for fingernail and toenail infections, and Parlodel, a dopamine agonist that treats pituitary-caused disorders. The agreement includes rights to manufacture the drugs and a joint marketing license for the Swiss market in addition to the China rights. Financial details were not disclosed. More details.... Stock Symbols: (HK: 0867) (NYSE: NVS) Share this with colleagues: // //